Eosinophilic Duodenitis Diagnosis

Diagnosis combines compatible gastrointestinal symptoms, upper endoscopy with adequate duodenal biopsies, histologic evidence of increased eosinophils, and evaluation for secondary causes such as infection, celiac disease, inflammatory bowel disease, medication reactions, and systemic eosinophilic disorders.

Biopsy is central because the mucosa may look normal or only mildly abnormal. Multiple samples improve detection of patchy disease and allow site-specific eosinophil counting and assessment of other microscopic features.

Testing may include CBC with differential, metabolic and nutritional studies, stool or parasite testing, celiac serology, medication review, EGD with biopsies, and targeted testing for inflammatory, infectious, allergic, or systemic disorders based on the clinical picture.

EoD is defined by eosinophil-predominant duodenal inflammation after secondary causes are excluded. Celiac disease, Crohn disease, infections, and drug reactions have different clinical, serologic, endoscopic, and histologic patterns even though symptoms can overlap.

It is an immune-mediated eosinophilic gastrointestinal disorder and may occur with atopic disease or food-related immune responses. However, not every patient has a food allergy, and allergy testing alone cannot establish the diagnosis or select a treatment diet.

A pathologist counts eosinophils in tissue biopsies and interprets the number by anatomic site and associated microscopic changes. There is no single universally accepted adult cutoff, so counts are interpreted with symptoms, biopsy distribution, and exclusion of other causes.

Treatment may include supervised dietary therapy, corticosteroids such as systemic steroids or selected budesonide approaches, treatment of coexisting acid-related disease, nutritional replacement, and specialist-directed options for refractory disease.

Empiric elimination or elemental diets may be considered in selected patients, but evidence is limited and restrictive diets can create nutritional and quality-of-life burdens. Dietitian supervision is important when multiple foods are removed.

Corticosteroids are the best-established anti-inflammatory medications for non-EoE eosinophilic gastrointestinal disease. Proton pump inhibitors may be used for coexisting acid-related disease or ulceration, while biologic and other immune-directed therapies remain more individualized or investigational.

There is no single duration. Induction therapy may last weeks, while chronic or relapsing disease may need longer management. Duration should be guided by symptom response, histology when reassessed, nutritional status, adverse effects, and recurrence risk.

Yes. Non-EoE eosinophilic gastrointestinal disorders can relapse after improvement or during treatment reduction. Recurrence may involve symptoms, tissue inflammation, or both, so long-term follow-up is individualized.

Persistent disease may contribute to chronic pain, vomiting, diarrhea, weight loss, anemia, low protein, nutritional deficiencies, ulceration, and reduced quality of life. More extensive or deeper eosinophilic disease can rarely cause obstruction or other complications.

Response can be tracked through symptoms, weight and nutrition, blood abnormalities when relevant, and repeat endoscopy with biopsy in selected patients. Symptoms alone may not reliably show whether microscopic inflammation has resolved.

Important factors include symptom severity, biopsy burden and distribution, nutritional impact, disease extent, atopic conditions, secondary-cause evaluation, prior treatment response, medication risks, and the patient’s ability to follow a dietary plan.

Specialist care is appropriate for persistent unexplained upper-GI symptoms, abnormal duodenal eosinophil counts, weight loss, recurrent vomiting, nutritional abnormalities, or treatment-resistant symptoms. Severe pain, bleeding, dehydration, or obstruction symptoms require urgent care.